Keryx Biopharmaceuticals
In David Abrams's portfolio · Abrams Capital Management
Ticker KERX
Not in the portfolio as of Q3 2026. Every quarter it shows up in a Abrams Capital Management 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q4 2018 | Sell | 0 | |
| Q3 2018 | Reduce 8% | 9,108,867 | 0.8% |
| Q2 2018 | Add 2% | 9,950,055 | 1.0% |
| Q1 2018 | No change | 9,719,176 | 1.2% |
| Q4 2017 | Add 70% | 9,719,176 | 1.5% |
| Q3 2017 | No change | 5,719,176 | 1.6% |
| Q2 2017 | No change | 5,719,176 | 1.6% |
| Q1 2017 | No change | 5,719,176 | 1.4% |
| Q4 2016 | No change | 5,719,176 | 1.2% |
| Q3 2016 | No change | 5,719,176 | 1.5% |
| Q2 2016 | No change | 5,719,176 | 2.0% |
| Q1 2016 | Add 4% | 5,719,176 | 1.3% |
| Q4 2015 | Add 10% | 5,500,000 | 1.5% |
| Q3 2015 | Buy | 5,000,000 | 1.3% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.